Vitreoretinal Technologies, Inc. Announces the Enrollment of First Patients for Its Phase III Clinical Trial for Vitreosolve for Diabetic Retinopathy Patients in the U.S. and India IRVINE, Calif., April 3, 2008 (PRIME NEWSWIRE) -- Vitreoretinal Technologies, Inc. (VRT) today announced the enrollment of the first patients in a multinational Phase III clinical trial for evaluation...

Vitreoretinal Technologies Raises $8.8 Million in a Recent Financing IRVINE, Calif., Nov. 26, 2007 (PRIME NEWSWIRE) -- Vitreoretinal Technologies (VRT) recently closed on an $8.8 million Series A financing with lead investor De Novo Ventures and a group of private...